Magnetic Resonance Imaging Systems - US Analysis and Market Forecasts, New Report Launched

The global magnetic resonance imaging (MRI) market is a shifting, capital equipment market that is saturated with numerous players developing innovative technologies. Given their impressive safety and efficacy as well as non-invasive nature, MRI systems have seen continued adoption since they were first introduced to the healthcare market. Rapid advances in the field imaging along with the development of MRI safe technologies have greatly expanded the potential of therapeutic applications.

The US market will be driven by physician adoption of new systems, especially high-field devices, as a result of acceptable safety profiles for high-field strength devices and the decreasing cost of equipment. The MRI market in the US, currently valued at approximately $1,300m in 2013.

Scope

• An overview of Magnetic Resonance Imaging Systems, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized the US Magnetic Resonance Imaging Systems market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
• Investigation of current and future market competition for Magnetic Resonance Imaging Systems.
• Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
• Competitor assessment including device approval analysis and device sales forecasts.
• Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
• Analysis of unmet needs within the market and opportunities for future players.
• Technology trends evaluation to assess strength of pipeline.
• An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
• Company profiles including business description, financial overview and SWOT analysis.
• Coverage of key market players.
• Strategic assessment of the Magnetic Resonance Imaging Systems sector through market impact analysis, future market scenario and company analysis.
• Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

• Understand the trends shaping and driving the US Magnetic Resonance Imaging Systems market.
• Realize device preferences of physicians who have performed the tests already.
• Access market sizing, forecasts and quantified growth opportunities in the US Magnetic Resonance Imaging Systems market through 2018.
• Quantify candidate patient populations to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
• Perform benchmarking analysis of growth opportunities against currently marketed products.
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
• What’s the next big thing in the US Magnetic Resonance Imaging Systems market landscape? Identify, understand and capitalize.

Spanning over 149 pages, “MediPoint: Magnetic Resonance Imaging Systems - US Analysis and Market Forecasts” report covering the Introduction, Industry Overview, Unmet Needs, Market Opportunity Analysis, Market Drivers and Barriers, Competitive Assessment, Pipeline Assessment, Current and Future Players, Stategic Competitive Assessment, Market Outlooks by Market Segment, Market Outlooks by Geography, Appendix. The Report covered companies are - Aurora Imaging, China Resources Wandong Medical Equipment, Esaote S.p.A., Fonar Corporation, GE Healthcare, Hitachi Medical Corporation, Hologic, Mindray, Neusoft Medical, Ningbo Xingaoyi Medical, Philips Healthcare, Siemens Healthcare, Sina Healthcare, Time Medical, Toshiba Medical Systems Corporation

For more information see - http://mrr.cm/4oz

Global MRI Systems Market Expected to reach $9.2 billion by 2020, Finds New Report

Magnetic Resonance Imaging Market Overview

Several attributes of X-ray imaging have limited its use over the years, specifically patient exposure to radiation and imaging-related issues such as poor resolution, depth, and contrast. However, the advent of next-generation imaging technologies has changed all that. The ability to achieve millimeter or even sub-millimeter spatial resolution with new X-ray computer tomography (CT) and magnetic resonance imaging (MRI) scanners has accelerated the use of non-invasive imaging and opened the door to a broad set of advanced applications. Nuclear imaging, particularly positron emission tomography (PET), has significantly progressed as well. While PET and CT are quickly becoming a critical component of clinical diagnoses, they are limited by image artifacts related to the scanning pattern: CT and PET images are acquired sequentially, rather than simultaneously, which means that artifacts can be caused by intra- and inter-scan patient and organ motion as well as differences between the breathing protocols used in PET and CT. These artifacts can severely impact the accuracy of the scanner and its attenuation correction, seriously compromising the imaging capability. MRI does not have these problems, and provides a large variety of protocols that selectively enhance contrast and thus provide enhanced visual discrimination among different tissues in vivo, and which can be utilized for dynamic contrast-enhanced imaging, diffusion imaging, functional MRI, and other purposes. Most importantly, MRI is also capable of spectroscopy for detection of organ-specific abnormalities. With significant advances in the MRI field, devices are more powerful and accurate than ever.

Increased utility and ever-rising desirability will drive the global MRI systems market to grow from $3.7 billion in 2012 to over $9.2 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 11.8% during the forecast period.

There are a number of key drivers for the adoption of MRI systems globally, including:

• Rising prevalence of diseases
• Increased demand for cost-effective and quality healthcare
• Novel technologies driving innovation
• Increased awareness of radiation dosage
• Open and partial MRI systems to drive further adoption, especially for claustrophobic patients
• Expanding use of MRI techniques by non-radiologists
• Steady reimbursement and other government funding
• Ever-growing global population

Despite increasing adoption, MRI system sales still face many market barriers, such as:

• US medical device excise tax
• Limited availability of venture capital
• Reduced hospital budgets
• Increasing prevalence of lifestyle-related diseases
• Ever-present competition from CT systems
• Shortage of dedicated MRI technologists
• High initial cost of capital equipment
• Lack of long-term data on use of MRI in patients

Regardless of market obstacles, Publisher expects steady growth in the MRI systems market, which is still in its infancy in many countries. Continued growth in this sector will be fueled by continual design developments, cost reductions, reimbursement improvements, and technology adoption in emerging markets.

Emerging Markets to Fuel New System Adoption

Emerging economies such as China and India are expected to continue to provide opportunities for revenue growth in the global MRI market. According to Publisher estimates, the Indian and Chinese markets accounted for 3.6% and 16.5% of global MRI systems revenue in 2012, respectively; this share is expected to increase further during the forecast period as physician adoption increases, reimbursement improves, and prices decline.

New sales growth in these emerging regions is expected to be fueled by the rapid uptake of less-expensive MRI systems that will allow access to healthcare in more remote areas of these price-sensitive economies. With increases in average income, growing demand for healthcare, and higher standards for care, these emerging markets are expected to see a rise in MRI procedures, as these systems offer safe and valuable insight into patient conditions and are a powerful decision-making tool for physicians.

Future Market Growth

The recent economic downturn has had a continued effect on MRI system sales, especially because competing technologies are cheaper and in many cases offer equal imaging quality and resolution. However, despite competition from other diagnostic devices, MRI systems have experienced continued adoption as cost-effectiveness improves and innovation drives technology improvements. The market growth for MRI systems in the US and EU is heavily dependent on the replacement of existing systems that are nearing the end of their lifetime. As such, the capacity for new installations in developed countries is limited, and as world economies recover, it can be expected that equipment replacement rates will increase in the future.

Despite the need for replacements, hospitals do not always decommission MRI systems at the end of the product’s manufacturer-recommended lifecycle, which negatively affects the sales of systems in these developed markets as companies forgo new system purchases. Additionally, a “trickling down” of MRI system features negatively impacts sales in developed countries: older high-end systems are sometimes replaced with low-end or mid-range systems, sacrificing features for cost savings. Finally, newer systems are expected to cost less, reducing the profit margins of manufacturers in this space. As a result, the MRI market is expected to be highly competitive.

Changes to reimbursement, the increasing aging population, rising prevalence of disease, and the escalating need for advanced imaging systems will act as major drivers for continued growth in the MRI market. Despite cost-containment measures implemented by healthcare authorities, the safety and efficacy of MRI techniques will continue to drive new sales in developed and emerging markets.

For more information see - http://mrr.cm/4oA

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices

Market Digest: Multiparameter Patient Monitoring Devices 2006 to 2020 - Europe (Germany, France, Italy, UK and Spain), New Report Launched

Market Digest: Multiparameter Patient Monitoring Devices 2006 to 2020 - Europe (Germany, France, Italy, UK and Spain) report provides quantitative analysis of the four multiparameter patient monitoring devices market segments: high acuity monitors, mid acuity monitors, low acuity monitors and multiparameter central stations. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: Germany, France, UK, Italy and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Publisher’s team of industry experts.

Scope

• Information on market size for the four multiparameter patient monitoring devices market segments: high acuity monitors, mid acuity monitors, low acuity monitors and multiparameter central stations
• Annualized sales data by revenue for the 2006–2020 period and company share data by revenue for 2013
• Annualized sales data by volume for the 2006–2020 period
• Coverage of key geographies: Germany, France, UK, Italy and Spain

Reasons to buy

• Derive actionable insights from value-volume relationships
• Analyze value-volume relationships and provide direction to marketing and sales strategies
• Develop market-entry and market-expansion strategies
• Identify the key players best positioned to take advantage of opportunities in the European market

Spanning over 66 pages, “Market Digest: Multiparameter Patient Monitoring Devices 2006 to 2020 - Europe (Germany, France, Italy, UK and Spain)” report covering the Definitions, Multiparameter Patient Monitoring Devices Market, Europe, Revenue, 2006–2020, Multiparameter Patient Monitoring Devices Market, Germany, Revenue and Volume, 2006–2020, Multiparameter Patient Monitoring Devices Market, France, Revenue and Volume, 2006–2020, Multiparameter Patient Monitoring Devices Market, UK, Revenue and Volume, 2006–2020, Multiparameter Patient Monitoring Devices Market, Italy, Revenue and Volume, 2006–2020, Multiparameter Patient Monitoring Devices Market, Spain, Revenue and Volume, 2006–2020, Appendix.

For more information see - http://mrr.cm/44R

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices

Prostate Cancer - Identifying and Commercializing First-in-Class Innovation, New Report Launched

Exceptionally Large and Innovative Pipeline

The prostate cancer pipeline is among the largest in the pharmaceutical industry with 484 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations in this pipeline is exceptional; Publisher analysis identified 174 first-in-class programs in the prostate cancer pipeline, acting on 122 first-in-class molecular targets. This accounts for some 36% of all products with a disclosed molecular target and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as, despite the high attrition rate in prostate cancer, it is highly likely many of the first-in-class technologies will reach the market over the coming decade and may transform the clinical and commercial landscape.

Alignment of First-in-Class Molecular Target with Disease Causation

One of the key trends in oncology and in prostate cancer in particular over the last decade is the clinical and commercial impact of targeted therapies designed to target proteins in signaling pathways that are strongly associated with disease progression. By aligning the molecular targets for therapeutic intervention with disease causation and/or propagation, these therapies limit the systemic cytotoxic effects whilst inhibiting tumor-promoting signaling pathways. Such strategies thereby typically achieve superior efficacy and safety profiles.

Our proprietary analyses demonstrate significant levels of differentiation as to how well the first-in-class products and their respective molecular targets align to underlying gene and protein level mutations and dysfunction. More advanced analytics further substantiated these findings as strong levels of differentiation in the scientific and clinical rationale for first-in-class molecular targets emerged. Furthermore, clear frontrunners were identified by integrating analyses to assess the accessibility of molecular targets for therapeutic compounds, the size of the target patient population that would benefit from therapeutic intervention, and the expected positioning of the first-in-class products based on the molecular targets and mechanisms of action of currently marketed products.

These insights and a detailed review of the available evidence from scientific studies substantiate the perspective that first-in-class-product technology in its own right is not sufficient to offer a compelling scientific and clinical rationale. However, a range of products offer very significant scientific and clinical promise and could therefore result in a strong commercial proposition with the prospect of clinically and commercially transformative products in the future.

A Deals Landscape with Numerous Investment Opportunities

Analysis has confirmed that 169 of the 174 first-in-class products have not been involved in a licensing or co-development deal. Although many act on targets that are not yet strongly substantiated in terms of their therapeutic potential in prostate cancer in clinical studies, there are many which are supported by promising in vivo and in vitro preclinical evidence, and as such are highly promising prostate cancer therapies. Indeed, breakthrough innovations are highly desirable as an investment option.

However, most deals involving first-in-class products were either preclinical or Phase I development, whereas advance-in-class and addition-to-class product deals were typically made in Phases II and III, therefore showing significant differentiation. These findings have significant strategic implications for both biotech companies seeking to out-license products and firms with an interest in in-licensing first-in-class products with strong clinical and commercial prospects.

Scope

The report analyzes innovation in prostate cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzed the deals landscape surrounding first-in-class products in prostate cancer, and pinpoints opportunities for in-licensing. The report covers and includes -

• A brief introduction to prostate cancer, including symptoms, pathophysiology, and overview of pharmacotherapy and treatment algorithms.
• The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline.
• Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
• Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
• Assessment of the licensing and co-development deal landscape for prostate cancer therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to -

• Understanding of the focal shifts in molecular targets in the prostate cancer pipeline.
• Understanding of the distribution of pipeline programs by phase of development, molecule type and molecular target.
• Access a scientific and clinical analysis of first-in-class developmental programs for prostate cancer, benchmarked against non-first-in-class targets.
• Access a list of the first-in-class therapies potentially open to deal-making opportunities

Spanning over 91 pages, “Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation” report covering the Executive Summary, The Case for Innovation in Prostate Cancer, Clinical and Commercial Landscape, Assessment of Pipeline Product Innovation, Signaling Network, Disease Causation and Innovation Alignment, First-in-Class Target and Pipeline Program Evaluation, Deals and Strategic Consolidations, Appendix.

For more information see - http://mrr.cm/44a

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Catheterization Laboratory Market in India 2014, New Report Launched

Catheterization Laboratory Market in India 2014 report states that the Indian market for catheterization laboratories is growing steadily as a result of the advancements in technology and the resultant increase in demand from hospitals, nursing homes and other medical centers. Different segments are available in the market which includes the premium, performance and value segments.

The rising incidence of cardiac diseases in the country and the increasing need for various medical procedures conducted in cath labs is however the most important growth factor for the market. Due to the growing target base, that is, healthcare centers, the market has huge potential for growth, thereby bringing immense benefit to players.

Several technological trends are visible in the market. With the rapid advancement and development of newer technologies, the market will get a further boost. Both domestic and foreign companies operate in the market and high competitive rivalry exists between them. However, Philips, GE and Siemens cumulatively hold the highest share in the market. The expansion of hospitals in tier II and tier III cities will help the Indian companies as these centers generally have a budget constraint and would prefer to buy the products of domestic manufacturers who generally sell their products at a lower price than those of foreign manufacturers.

Spanning over 76 pages “Catheterization Laboratory Market in India 2014” report Covering Executive Summary, Macroeconomic Indicators, Introduction, Market Overview, Drivers & Challenges, Technological Trends, Competitive Landscape, Strategic Recommendation, Appendix. This report Covered Companies are - Siemens Ltd., Allengers Medical Systems Ltd., Komega Impex Pvt. Ltd., Masters Medical Equipments Pvt. Ltd., Erbis Engineering (India) Pvt. Ltd., GE Medical Systems (India) Pvt. Ltd., Philips India Ltd., Shimadzu Medical (India) Pvt. Ltd.

Know more about this report at – http://mrr.cm/44s

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

In Vitro Diagnostics Market in India 2014, New Report Launched

In Vitro Diagnostics Market in India 2014 report analyses the growth of the market due to improved technology and modern diagnostic tools which provides faster and accurate test results for the patients. The market can be segmented on the basis of the product type and the technology used. The technology market is sub-divided into the following sections such as immunochemistry, molecular diagnostics, hematology, coagulation, microbiology, biochemistry, urinalysis and blood gas and electrolyte. According to product type, the market can be further sub-divided into instruments and reagents.

Driven by factors such as high patient population, rise in the number of hospitals and diagnostic labs and other factors, the IVD market is experiencing a developing phase. The main challenges the market is experiencing are faulty regulations and laboratory without accreditation. Trends such as automation, remote data acquisition and other factors are helping the market to grow. The market is dominated by private player followed by public players. Decentralized testing, increasing automated laboratories, increasing consolidation and demand for early detection of diseases will contribute towards the growth of the market in the following years

Spanning over 128 pages, “In Vitro Diagnostics Market in India 2014” report covering the Executive Summary, Introduction, Market Overview, Drivers & Challenges, Laws and Guidelines, Market Trends, Competitive Landscape, Future Outlook, Strategic Recommendations, Appendix. The report covered companies are - Piramal Healthcare Ltd., Siemens Ltd., Span Diagnostics Ltd., Agappe Diagnostics Limited, Life Technologies India Private Limited, BioMérieux India Private Limited, Trivitron Healthcare Pvt. Ltd., Transasia Bio-medicals Pvt. Ltd., Beckman Coulter India Pvt. Ltd., Becton Dickinson India Pvt. Ltd., Roche Diagnostics India Pvt. Ltd., Sysmex India Pvt. Ltd., Tulip Diagnostics India Pvt. Ltd., Thermo Fisher Scientific India Pvt. Ltd., Alere Medical Private Limited

For more information see - http://mrr.cm/44A

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices

Medical Diagnostics Market in India 2014, New Report Launched

Medical Diagnostics Market in India 2014 report analyses the growth of the market due to cutting edge technology which provides better disease diagnosis. The Indian diagnostics market can be divided into equipment, reagents and services. The service sector is characterized by a large number of laboratories in the unorganized sector, which are clustered in the suburban areas and metros. In order to have better regulations and proper definition for the market a clear and structured format is being established. The laboratories are rapidly expanding using various business models. Large numbers of laboratories are registered only with the state health departments and not recognized by NABL (National Accreditation Board for Testing and Calibration Laboratories under Department of Science and Technology, Govt. of India).

The market is driven by increasing number of lifestyle diseases, rise in life expectancy due to preventive healthcare practices and increasing medical tourism. Currently there is trend of diagnostic medical imaging due to innovation in the technology sector which is helping the market to grow. Few numbers of accredited labs and high dependence on imported medical diagnostics products are the challenges this market is facing. Even though a range of diagnostic tests for various diseases are available in the market, there is a need for more reliable and better diagnostics. The market is dominated by private diagnostics companies in India who are expanding in Tier I and Tier II cities. Providing after-sales services for medical instruments and competitive pricing of the tests will catalyze the growth of the diagnostic sector.

Spanning over 71 pages, “Medical Diagnostics Market in India 2014” report covering the Executive Summary, Introduction, Market Overview, Drivers & Challenges, Trends, Government Regulations, Competitive Landscape, Strategic Recommendations, Appendix. The report covered companies are - Piramal Healthcare Ltd., Apollo Health and Lifestyle Ltd., Dr. Lal Pathlabs Pvt. Ltd., Metropolis Healthcare Ltd., Quest Diagnostics India Pvt. Ltd., S Serum Analysis Centre Pvt. Ltd., SRL Diagnostics Pvt. Ltd., Thyrocare Diagnostics Pvt. Ltd.

For more information see - http://mrr.cm/44M

Find all Diagnostics Reports at: http://www.marketresearchreports.com/diagnostics

Global Transdermal Drug Delivery Market to 2017, New Report Launched

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 320 tables & figures over 280 pages. 

This report is presented as follows:

• By Company (e.g., JANSSEN, MYLAN, ACTAVIS, GLAXOSMITHKLINE, BAYER, NOVARTIS, NOVEN, LAVIPHARM, PROSTRACKEN, NITTO DENTO)
• By Geography (Global, USA)
• By Parent Market (Drug Delivery Systems, Advanced Drug Delivery Systems)
• By Sub-market (Generics, Women’s Health, Analgesics, Neuropathic Pain)

A wealth of financial data & business strategy information is provided including:

• Up-to-date company financials, sales & revenue figures
• Revenue and market forecasts
• Business model strategies for drug delivery, pharmaceutical and biotechnology companies
• Comprehensive account of company products, financials & portfolios

SWOT, Economic & Regulatory Environment specifics include:

• Key strengths, weaknesses and threats influencing leading player position within the market
• Technologies driving the market (e.g., chemical enhancers, microneedles)
• Top fastest growing market segments and emerging opportunities
• Top pharmaceutical companies within the market
• Comprehensive product portfolios, R&D activity and pipeline products
• M&A activity and future strategies of top companies
• High demand and unmet need enhances the market
• Challenges of the transdermal drug delivery market

Who should read this report?

• Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
• Industry professionals and business strategists will discover key information to propel their policies
• Investors will gain inside information to dominant players in the industry and future forecasts
• Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment C-Suite professionals, Decision Makers, Business Development professionals

This report will tell you if the companies mentioned are:

• Strong, competitive players
• Pooling their resources for specific growth and therapeutic areas
• Investing strategically in R&D
• Have a history of strategic M&A activity

This detailed report is supported with 320 figures and tables over 280 pages and profiles the main pharmacos in the transdermal drug delivery market.

Benefits of Investing in our Cutting-Edge Reports:

• Clients receive complementary content* with mid-level and enterprise wide licences.
• Post-sale complementary consultation with senior expert analyst is included.
• Use of tables and figures in your own reports and presentations is permitted.
• Each report provides straight-talking strategic analysis & sector intelligence.
• All reports are updated each quarter to give you the most up-to-date information.

Spanning over 280 pages, “Global Transdermal Drug Delivery Market to 2017” report covering the Executive Summary, Transdermal Drug Delivery, Biomechanical and Pharmacological Elements Effecting Transdermal Drug Delivery, Transdermal Drug Delivery Technologies, How Nanotechnology is Transforming Transdermal Drug Delivery, Transdermal Drug Delivery and Disease States, Gene Therapy and Transdermal Drug Delivery, Vaccines and Transdermal Drug Technology, Global Drug Delivery Market, Transdermal Drug Delivery Company Business Profiles and Strategic Evaluation, Transdermal Drug Delivery Company Financial Analysis, Current Transdermal Drug Delivery Products on the Market, In-Depth SWOT Analysis of the Transdermal Drug Delivery Market. The report covered 23 companies are - 3M, AMAG Pharmaceuticals (Lumara Health, KV Pharm/Ther-Rx Corp), Actavis, Actelion, Ascend Therapeutics, Bayer, Boehringer Ingelheim, Endo International, GlaxoSmithKline, Hercon Pharmaceutical, Janssen Pharmaceuticals, Kremers Urban Pharmaceuticals, Mylan Pharmaceuticals, Nitto Denko, Novartis, Noven Pharmaceuticals, ParPharm, ProStrakan, Shire, Teikoku USA, Teva Pharmaceutical Industries, UCB, Upsher-Smith.

For more information see – http://mrr.cm/44Z

Find all Drug Delivery Reports at: http://www.marketresearchreports.com/drug-delivery

Hearing Aids Market in India 2014, New Report Launched

Hearing Aids Market in India 2014 report states that the demand for hearing aids is increasing in the country due to a number of reasons, with the changing demographic pattern of the country being the leading factor. With the population of elderly growing in India, loss of hearing is plaguing a vast number of Indians and has resulted in an increasing use of hearing aids. Moreover, changes in the perception of patients and growing awareness regarding hearing aids are further helping in the growth of the industry. The social stigma attached to wearing hearing aids, which was present till even a few years back, has reduced drastically. This has provided a further boost to the industry. Most companies operating in the market sell both analog and digital models, although the number of analog models on offer is considerably less compared to the digital models on offer. This is due to the rapid shift of preference from analog to digital models, both for new consumers as well as existing consumers.

Currently, the market is dominated by foreign players who manufacture their products in their overseas facilities and market it in India through their local subsidiaries. However, there are a few domestic players who mostly try to compete with the foreign companies by providing no-frills products at a lower price than those of foreign products. Growing market penetration, especially in smaller cities and towns, is helping the market to grow. Overall, the market is exhibiting steady growth and promises ample opportunities to all the players operating in the market.

Spanning over 51 pages, “Hearing Aids Market in India 2014” report covering the Executive Summary, Introduction, Market Overview, Drivers & Challenges, Trends, Competitive Landscape, Strategic Recommendation, Appendix. The report covered companies are - Nobel Biocare India Pvt. Ltd., Dentsply India Pvt. Ltd., Osstem Implant India Pvt. Ltd., Life Care Devices Pvt. Ltd., Sark Healthcare Pvt. Ltd.

For more information see - http://mrr.cm/44o

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices

Dental Implant Market in India 2014, New Report Launched

Dental Implant Market in India 2014 report states that the demand for dental implant is rising in the country due to various reasons. The huge population of the country comprising a large number of elderly people has resulted in a strong case for the growth of dental services. The number of dental clinics being set up in the country has been increasing and is making dental services more accessible and affordable; in turn leading to a rise in the demand for dental implant. With a large number of patients suffering from edentulism and awareness about the advantages of dental implant growing, demand for this product is expected to grow strongly in the coming years. Growth in dental tourism is another factor aiding growth in the market since the entire dental implant procedure costs much lesser in India compared to the developed Western countries.

The dental implant market in India is characterized by the presence of very few players with mostly foreign companies operating in this market. High competitive rivalry exists between the foreign manufacturers while the Indian companies are still looking to make a mark in the industry. Overall, the market is exhibiting steady growth and promises ample opportunities to all the players operating in the market. Efforts to develop cheap dental implants are in progress and any breakthrough in this effort will help the market to grow further.

Spanning over 83 pages, “Dental Implant Market in India 2014” report covering the Executive Summary, Introduction, Market Overview, Product Prices, EXIM, Drivers & Challenges, Competitive Landscape, Strategic Recommendation, Appendix. The report covered companies are - Siemens Ltd., Alps International Pvt. Ltd., Elkon Pvt. Ltd., Starkey Laboratories India Pvt. Ltd., Unitron Hearing India Pvt. Ltd, Widex India Pvt. Ltd., Phonak India Pvt. Ltd., Bernafon AG

For more information see - http://mrr.cm/444

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Oncology Pharmaceuticals Market in India 2014, New Report Launched

Oncology Pharmaceutical Market in India 2014 report highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing number of cancer cases are the key drivers of this market. Lung, stomach, colon and breast cancer cause the maximum number of cancer deaths each year. Pharmaceutical companies are progressively increasing R&D expenditure on cancer vaccines. The growing number of patients seeking treatment for cancer has made hospitals realize that cancer treatment is an important area for growth. Gleevec, Mabthera, Iressa, Avastin, Grafeel, Soliris and Herceptin are the top selling cancer drugs in the Indian market.

Alternative therapies such as cancer gene therapy and cancer cell therapy are increasingly becoming popular in cases where conventional therapies have failed. Combination therapies are being increasingly used in cancer treatments. Some challenges faced by the industry are the internal competition between large pharmaceutical companies. Another challenge is the penetration of Oncological drugs in rural areas which is very low. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well. Manufacture of generic oncology drugs will help the pharmaceutical manufacturer gain a competitive advantage over others in a highly competitive pharma market. Companies should focus on development of new molecules in order to prolong the longevity of a blockbuster drug in the market.

Spanning over 90 pages, “Oncology Pharmaceuticals Market in India 2014” report covering the Executive Summary, Introduction, Market Overview, Export-Import, Value Chain, Drivers & Challenges, Government Initiatives, Government Initiatives, Regulations, Competitive Landscape, Recent Developments, Strategic Recommendation, Appendix. The report covered companies are - Sanofi India Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Novartis India Ltd., Merck Ltd., Pfizer Ltd., Ranbaxy Laboratories Ltd., Johnson and Johnson Ltd., Roche Pharmaceuticals Pvt. Ltd.

For more information see - http://mrr.cm/4Zv

Find all Oncology Reports at: http://www.marketresearchreports.com/oncology

Nuclear Imaging - PET and SPECT Equipment - Global Analysis and Market Forecasts, New Report Launched

Nuclear Imaging Market Overview

Publisher estimates the global nuclear imaging market to have been worth $1.77 billion in 2012 and $1.83 billion in 2013. Publisher estimates that this market will be worth $2.2 billion in 2020, increasing at a Compound Annual Growth Rate (CAGR) of 3.3% during the period of 2014 to 2020.

The key drivers for the global nuclear imaging market are:

• Aging population and increasing disease prevalence
• Increasing referring physician awareness
• Increasing defensive medicine
• Increasing patient awareness
• Increasing self-referral behavior
• Increasing implementation of comparative effectiveness research
• Improved accreditation of imaging facilities
• Availability of new imaging reagents
• Increasing demand for cancer diagnoses
• Increasing demand for imaging-based companion diagnostics
• Replacement of positron emission tomography (PET)/computed tomography (CT) by PET/magnetic resonance imaging (MRI)
• Replacement of single-photon emission computed tomography (SPECT)-only systems

The key barriers of the global nuclear imaging market are:

• Legislation affecting reimbursements
• The lobbying efforts of medical insurance companies and consequent reduction in the number of procedures performed
• Greater scrutiny of electronic medical records by healthcare payers, leading to a reduction in the number of procedures performed.
• Increased use of appropriateness criteria, resulting in reduced examinations
• Practice guidelines reducing unnecessary procedures
• Loss of nuclear medicine skills
• High cost of instruments and reagents
• Supply difficulties and increasing cost of radio-pharmaceuticals
• Medical Device Excise tax increasing development costs
• Hospital consolidation reducing the number of scanning facilities

The nuclear imaging market is a moderately growing market with a 2014-2020 CAGR of 3.3% globally. It is a mature sector of the diagnostic imaging market; continued growth is expected along with continued technological developments and the emerging markets’ acceptance of products.

US Dominates the Nuclear Imaging Market

In 2012, the US dominated the global nuclear imaging market, accounting for 69% of sales globally. The market is dominated by three companies: the market leader is Philips Healthcare with around 35% of the market by revenue, followed closely by GE Healthcare with around 33% of the market, and Siemens Healthcare at just under 30%.

Demand for Nuclear Imaging in US to Become Static

The US is the largest market for nuclear imaging, in terms of the number of systems sold and the number of procedures carried out. However, a period of a rapid increase in procedures in the US, particularly PET and PET/CT, has led to measures to reduce the number of procedures that can be reimbursed, and thus reduce the demand for nuclear imaging systems. Prior to healthcare reform, the major threat to the US nuclear imaging market was the limited supply of radiopharmaceuticals.

APAC to Foster Future Growth

APAC economies. especially China and Japan, will continue to provide immense opportunities for increasing sales within the global nuclear imaging market. Publisher projects that Japan will increase its market share by 75% and that China will almost double its market share.

Publisher expects that the growth of sales in China will be attributed in part to the sale of more PET/CT and SPECT/CT systems, whereas in Japan, growth will be due to increasing demand for SPECT/CT and PET/MRI systems.

Future Outlook

The economic downturn has been a continued concern within the whole of the diagnostic imaging market. Indeed, the high cost of nuclear imaging equipment and procedures has made the nuclear imaging market more susceptible to the downturn. The market growth for nuclear imaging in the US and EU is heavily dependent on the replacement of already existing systems because, as is the case in most of the developed countries, the capacity for new installations is limited. As the US and EU economies recover, it can be expected that the equipment will be replaced.

However, at this point in time, the key opinion leaders (KOLs) that Publisher interviewed for this report indicated that not all equipment is replaced at the end of the average product lifecycle, negatively affecting sales in the US and EU markets.

The rising prevalence of disease, an aging population, and a growing global population will act as major drivers of the increased use of nuclear imaging. However, cost-containment measures implemented by healthcare authorities will affect which nuclear imaging technologies are favored.

For more information see – http://mrr.cm/4Z9

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices